Risks associated with Sirolimus and COVID-19
Sirolimus is efficient for immunosuppression in transplant patients
where it acts prophylactically especially in renal transplant. It
increases susceptibility to infection due to which patients are at high
risk for COVID-19. It can cause complications like lowering of lung
function like FEV1 (forced expiratory volume). It is important to follow
CDC guidelines as recommended. Moreover, it is also advised that LAM
(lymphangioleiomyomatosis) patients who suffer from abnormal growth of
muscle like cells in lungs, lymph nodes or kidneys are at high risk of
contracting COVID-19 due to intake of Sirolimus. But, due to the nature
of their illness, it is advisable that they continue with their
treatment plan. It is important for the healthcare provider to decide
upon dose reduction or treatment interruption in certain circumstances
wherein patients are at high risk of COVID-19 transmission [22].